Crossbow Therapeutics
PrivateLast Round
Series B
Mar 18, 2026
Est. Valuation
$112.55M
Total Funding Raised
$157M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Crossbow Therapeutics is a biotechnology company developing next-generation T-cell receptor (TCR)-mimetic antibody therapies to treat a broad range of cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crossbow Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Crossbow Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 18, 2026 | ||||
| Series A | Jul 11, 2023 |
Key People
Founding team and executive leadership
Crossbow Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Libbs Ventures | Series B |
| LifeLink Ventures | Series B |
| Sixty Degree Capital | Series B |
| Taiho Ventures | Series B |
| MPM BioImpact | Series B, Series A, Seed |
| Arkin Bio Capital | Series B |
| BVF Partners L.P. | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 18, 2026
$77M round completed.
- Mar 18, 2026
Developing novel T-cell engager therapies targeting cancer cells.
Crossbow Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Crossbow Therapeutics's valuation, stock price, and market status.